217 related articles for article (PubMed ID: 12490770)
21. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
22. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Hilton RC; Rengasamy M; Mansoor B; He J; Mayes T; Emslie GJ; Porta G; Clarke GN; Wagner KD; Birmaher B; Keller MB; Ryan N; Shamseddeen W; Asarnow JR; Brent DA
J Am Acad Child Adolesc Psychiatry; 2013 May; 52(5):482-92. PubMed ID: 23622849
[TBL] [Abstract][Full Text] [Related]
23. Paroxetine: an update of its use in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
Drugs; 2002; 62(4):655-703. PubMed ID: 11893234
[TBL] [Abstract][Full Text] [Related]
24. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
Sheehan DV; Eaddy MT; Shah MB; Mauch RP
Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
[TBL] [Abstract][Full Text] [Related]
25. Moclobemide versus fluoxetine in the treatment of inpatients with major depression.
Gattaz WF; Vogel P; Kick H; Kohnen R
J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):35S-40S. PubMed ID: 7593728
[TBL] [Abstract][Full Text] [Related]
26. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Perugi G; Frare F; Toni C; Ruffolo G; Torti C
Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
[TBL] [Abstract][Full Text] [Related]
27. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients.
Ferguson JM; Wesnes KA; Schwartz GE
Int Clin Psychopharmacol; 2003 Jan; 18(1):9-14. PubMed ID: 12490769
[TBL] [Abstract][Full Text] [Related]
28. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression.
Søgaard J; Lane R; Latimer P; Behnke K; Christiansen PE; Nielsen B; Ravindran AV; Reesal RT; Goodwin DP
J Psychopharmacol; 1999 Dec; 13(4):406-14. PubMed ID: 10667618
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Hawley CJ; Quick SJ; Ratnam S; Pattinson HA; McPhee S
Int Clin Psychopharmacol; 1996 Sep; 11(3):187-91. PubMed ID: 8923097
[TBL] [Abstract][Full Text] [Related]
30. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
Ball SG; Kuhn A; Wall D; Shekhar A; Goddard AW
J Clin Psychiatry; 2005 Jan; 66(1):94-9. PubMed ID: 15669894
[TBL] [Abstract][Full Text] [Related]
31. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Seedat S; Stein MB
J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
[TBL] [Abstract][Full Text] [Related]
32. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
Gibiino S; Mori E; De Ronchi D; Serretti A
J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine.
Gilmor ML; Owens MJ; Nemeroff CB
Am J Psychiatry; 2002 Oct; 159(10):1702-10. PubMed ID: 12359676
[TBL] [Abstract][Full Text] [Related]
34. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
Mohamed S; Osatuke K; Aslam M; Kasckow J
Am J Geriatr Pharmacother; 2006 Sep; 4(3):201-9. PubMed ID: 17062320
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
Stocchi F; Nordera G; Jokinen RH; Lepola UM; Hewett K; Bryson H; Iyengar MK;
J Clin Psychiatry; 2003 Mar; 64(3):250-8. PubMed ID: 12716265
[TBL] [Abstract][Full Text] [Related]
36. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
Bordet R; Thomas P; Dupuis B
Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
[TBL] [Abstract][Full Text] [Related]
37. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
38. Remission rates in patients with anxiety disorders treated with paroxetine.
Ballenger JC
J Clin Psychiatry; 2004 Dec; 65(12):1696-707. PubMed ID: 15641876
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
[TBL] [Abstract][Full Text] [Related]
40. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
